| Old | New | Differences | |
|---|---|---|---|
| 1 | 1 | ||
| 2 | 2 | ||
| 3 | 3 | LCO No. 2098 1 of 1 | |
| 4 | 4 | ||
| 5 | 5 | General Assembly Proposed Bill No. 6224 | |
| 6 | 6 | January Session, 2021 | |
| 7 | 7 | LCO No. 2098 | |
| 8 | 8 | ||
| 9 | 9 | ||
| 10 | 10 | Referred to Committee on GENERAL LAW | |
| 11 | 11 | ||
| 12 | 12 | ||
| 13 | 13 | Introduced by: | |
| 14 | 14 | REP. RYAN, 139th Dist. | |
| 15 | 15 | ||
| 16 | 16 | ||
| 17 | 17 | ||
| 18 | 18 | AN ACT PROMOTING DRUG PRICE TRANSPARENCY. | |
| 19 | 19 | Be it enacted by the Senate and House of Representatives in General | |
| 20 | 20 | Assembly convened: | |
| 21 | 21 | ||
| 22 | 22 | That the general statutes be amended to require drug manufacturers 1 | |
| 23 | 23 | to report drug price increases in excess of ten per cent in a twelve-month 2 | |
| 24 | 24 | period or in excess of sixteen per cent in a twenty-four-month period, to 3 | |
| 25 | 25 | require manufacturers to report specified information regarding new 4 | |
| 26 | 26 | brand name and generic prescription drugs with prices above certain 5 | |
| 27 | 27 | thresholds, and to require manufacturers to report specific information 6 | |
| 28 | 28 | regarding newly acquired brand name drugs having retail prices over 7 | |
| 29 | 29 | one hundred dollars for a thirty-day supply or generic drugs having 8 | |
| 30 | 30 | retail prices over fifty dollars for a thirty-day supply. 9 | |
| 31 | 31 | Statement of Purpose: | |
| 32 | 32 | To promote drug price transparency. |